本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）于近日收到中国证券 监督管理委员会《关于同意重庆智飞生物制品股份有限公司向专业投资者公开发 行科技创新公司债券注册的批复》（证监许可〔2025〕2255 号）,现将批复内容 公告如下： 证券代码：300122 证券简称：智飞生物 公告编号：2025-57 重庆智飞生物制品股份有限公司 关于向专业投资者公开发行科技创新公司债券注册申请获得 中国证券监督管理委员会同意注册批复的公告 特此公告 重庆智飞生物制品股份有限公司董事会 2025 年 10 月 15 日 1 四、自同意注册之日起至本次科技创新公司债券发行结束前，公司如发生重 大事项，应及时报告并按有关规定处理。 公司董事会将按照有关法律法规和上述批复文件的要求及公司股东大会的 授权，根据资金需求和市场情况择机发行科技创新公司债券，并及时履行信息披 露义务。 一、同意公司向专业投资者公开发行面值总额不超过 10 亿元科技创新公司 债券的注册申请。 二、本次发行科技创新公司债券应严格按照报送深圳证券交易所的募集说明 ...

13 October 2025 | 6:39PM CST Equity Research China Healthcare: 3Q25 preview: United Imaging & Lepu to lead revenue growth, Zhifei still at cycle trough Companies with higher revenue growth: We expect United Imaging to lead our coverage universe with a 44% yoy revenue growth in 3Q25. We believe the company's strong growth momentum is mainly driven by the improvement in China's hospital bidding data, which has begun to be reflected in its financial statements. We also expect Lepu to achieve rapid revenue grow ...

北京商报讯（记者 王寅浩 实习记者 宋雨盈）10月9日，智飞生物发布公告称，公司及全资子公司—— 北京智飞绿竹生物制药有限公司、安徽智飞龙科马生物制药有限公司于近日取得中华人民共和国国家知 识产权局颁发的发明专利证书，发明专利名称为一种可预防幽门螺杆菌感染的OMV疫苗及其制备方 法。 ...

每经AI快讯，智飞生物（SZ 300122，收盘价：20.96元）10月9日晚间发布公告称，重庆智飞生物制品 股份有限公司及全资子公司——北京智飞绿竹生物制药有限公司、安徽智飞龙科马生物制药有限公司于 近日取得中华人民共和国国家知识产权局颁发的发明专利证书。专利名称为"一种可预防幽门螺杆菌感 染的OMV 疫苗及其制备方法"。 每经头条（nbdtoutiao）——与美元脱钩后，暴涨102倍，揭秘黄金疯涨背后神秘的"无形之手"！专家： 推动金价上涨的逻辑没有变 （记者 王晓波） 截至发稿，智飞生物市值为502亿元。 2024年1至12月份，智飞生物的营业收入构成为：生物制品占比99.14%，其他业务占比0.86%。 ...

关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）及全资子公司——北 京智飞绿竹生物制药有限公司（以下简称"智飞绿竹"）、安徽智飞龙科马生物 制药有限公司（以下简称"智飞龙科马"）于近日取得中华人民共和国国家知识 产权局颁发的发明专利证书。具体情况如下： 证券代码：300122 证券简称：智飞生物 公告编号：2025-56 重庆智飞生物制品股份有限公司 上述发明专利是在公司在研管线产品的研发过程中申请获得，将在公司相关 在研产品上应用。该专利证书的取得不会对公司近期生产经营产生重大影响，但 有利于进一步完善公司知识产权保护体系，充分发挥自主知识产权优势，促进技 术创新，提升公司的核心竞争力。 特此公告 重庆智飞生物制品股份有限公司董事会 2025 年 10 月 9 日 1 | 发明专利名称 | 专利号 | 专利证书号 | 专利类型 | 专利申请日 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | --- | | 一种可预防幽门 ...

Group 1 - Double-Helix Pharmaceutical announced that its associate, Changfeng Pharmaceutical, is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 each. Double-Helix holds approximately 3.68% of Changfeng's shares, with a lock-up period of 12 months post-listing [1] - Changfeng Pharmaceutical is involved in the pharmaceutical industry, specifically in the research and development of gene-engineered drugs [2] Group 2 - Lio Corporation has submitted an application to the Hong Kong Stock Exchange for issuing H-shares and listing on the main board [3] - Lio Corporation operates in the mechanical manufacturing and digital marketing sectors [3] Group 3 - Changjiang Securities received approval from the China Securities Regulatory Commission to issue corporate bonds totaling no more than CNY 20 billion, valid for 24 months [4] - Changjiang Securities provides services such as securities and futures brokerage, financial product distribution, investment advisory, asset custody, and margin financing [4] Group 4 - Jingye Intelligent plans to acquire 51% of Hefei Shengwen Information Technology for CNY 108 million, focusing on engineering information technology and intelligent products [5][6] - Jingye Intelligent specializes in the research, development, production, and sales of special robots and intelligent equipment systems [6] Group 5 - Aimeike's subsidiary received approval for the registration of Minoxidil topical solution, a non-prescription drug for treating hair loss [7][8] - Aimeike is engaged in the research, development, production, and sales of biomedical materials and biopharmaceuticals [8] Group 6 - Dalian Heavy Industry expects a net profit of CNY 474 million to CNY 508 million for the first three quarters of 2025, representing a year-on-year increase of 19.91% to 28.52% [9] - Dalian Heavy Industry specializes in the design, manufacturing, assembly, and installation of major technical equipment [9] Group 7 - Huayou Cobalt signed supply agreements with LGES for a total of approximately 76,000 tons of ternary precursor products from 2026 to 2030 [10][11] - Huayou Cobalt focuses on the research, manufacturing, and sales of new energy lithium battery materials and cobalt new materials [11] Group 8 - Zhenjiang Co. plans to reduce its shareholding by up to 5.529 million shares, not exceeding 3% of the total share capital, due to personal funding needs [12] - Zhenjiang Co. is involved in the design, processing, and sales of wind power equipment and components [12] Group 9 - Watson Bio's subsidiary received a drug registration certificate for a 13-valent pneumococcal polysaccharide conjugate vaccine for children [14][15] - Watson Bio specializes in the research, development, production, and sales of human vaccines and biopharmaceuticals [15] Group 10 - Yikang Pharmaceutical's major shareholder plans to reduce holdings by up to 42 million shares, not exceeding 2.04% of the total share capital, due to personal funding needs [16] - Yikang Pharmaceutical is engaged in the production and sales of excipients, raw materials, finished drugs, and new energy materials [16] Group 11 - Sichuan Gold's shareholder plans to reduce holdings by up to 7.56 million shares, accounting for 1.80% of the total share capital [19] - Sichuan Gold focuses on the construction, mining, and sales of gold mines [19] Group 12 - Kangchen Pharmaceutical received approval for a clinical trial of an innovative drug for treating advanced esophageal squamous cell carcinoma [20][21] - Kangchen Pharmaceutical specializes in the manufacturing of chemical drug formulations [21] Group 13 - UCloud plans to repurchase shares worth between CNY 8 million and CNY 10 million for employee stock ownership plans [22] - UCloud provides cloud computing services centered on IT infrastructure [22] Group 14 - Woton Technology announced an adjustment to its share repurchase plan, raising the price cap to CNY 60 per share [24] - Woton Technology specializes in the research, manufacturing, and sales of separation membrane products [24] Group 15 - Five Continents Medical announced plans for shareholders to reduce holdings by up to 126,530 shares, accounting for 1.8606% of the total share capital [26] - Five Continents Medical focuses on the research, manufacturing, and sales of disposable sterile infusion medical devices [26] Group 16 - CIMC Group plans to repurchase A-shares with a total amount not exceeding CNY 5 billion [27] - CIMC Group specializes in logistics and energy equipment solutions [27] Group 17 - Zhifei Biological's subsidiary received a drug registration certificate for a trivalent influenza vaccine suitable for individuals aged 3 and above [29][30] - Zhifei Biological is involved in the research, development, production, and sales of vaccines and biological products [30]

格隆汇9月29日丨智飞生物(300122.SZ)公布，近日获悉，由公司全资子公司安徽智飞龙科马生物制药有 限公司（简称"智飞龙科马"）研发的流感病毒裂解疫苗（简称"三价流感疫苗"）获得国家药品监督管理 局出具的《药品注册证书》。 公司自主研发的流感病毒裂解疫苗成功获得《药品注册证书》，是公司坚持贯彻"技术&市场"双轮驱动 的重要成果，展现了公司创新研发实力，为公司进一步拓展市场奠定了坚实基础。本次获得药品注册证 书的三价流感疫苗，与公司已获批上市的四价流感病毒裂解疫苗、处于申报上市审评中的四价/三价流 感病毒裂解疫苗（儿童型）、处于I/Ⅱ期临床试验的四价流感病毒裂解疫苗（ZFA02佐剂）及已获批临 床的三价流感病毒裂解疫苗（ZFA02佐剂）构成覆盖全年龄段且种类丰富的流感疫苗系列产品。公司将 以更多优质产品服务民众健康需求，强化公司综合竞争力，促进公司实现持续稳健发展。 ...

公司自主研发的流感病毒裂解疫苗成功获得《药品注册证书》，是公司坚持贯彻"技术&市场"双轮驱动 的重要成果，展现了公司创新研发实力，为公司进一步拓展市场奠定了坚实基础。本次获得药品注册证 书的三价流感疫苗，与公司已获批上市的四价流感病毒裂解疫苗、处于申报上市审评中的四价/三价流 感病毒裂解疫苗（儿童型）、处于I/Ⅱ期临床试验的四价流感病毒裂解疫苗（ZFA02佐剂）及已获批临 床的三价流感病毒裂解疫苗（ZFA02佐剂）构成覆盖全年龄段且种类丰富的流感疫苗系列产品。公司将 以更多优质产品服务民众健康需求，强化公司综合竞争力，促进公司实现持续稳健发展。 格隆汇9月29日丨智飞生物(300122.SZ)公布，近日获悉，由公司全资子公司安徽智飞龙科马生物制药有 限公司（简称"智飞龙科马"）研发的流感病毒裂解疫苗（简称"三价流感疫苗"）获得国家药品监督管理 局出具的《药品注册证书》。 ...

每经头条（nbdtoutiao）——农夫大战怡宝，抢到更多蛋糕的却是宗馥莉！农夫绿瓶上市后，怡宝上 演"滑铁卢"：市占率大跌近5个百分点 （记者 张明双） 每经AI快讯，智飞生物（SZ 300122，收盘价：20.77元）9月29日晚间发布公告称，重庆智飞生物制品 股份有限公司及全资子公司——安徽智飞龙科马生物制药有限公司、北京智飞绿竹生物制药有限公司于 近日取得中华人民共和国国家知识产权局颁发的发明专利证书。专利名称为"一种免疫佐剂质量差异的 检测方法"。 2024年1至12月份，智飞生物的营业收入构成为：生物制品占比99.14%，其他业务占比0.86%。 截至发稿，智飞生物市值为497亿元。 ...

智飞生物(300122.SZ)公告称，公司全资子公司智飞龙科马研发的流感病毒裂解疫苗获得国家药品监督 管理局出具的《药品注册证书》。该疫苗适用于32岁及以上人群预防流感病毒引起的感染性疾病，是目 前国内外预防流感的最主要产品之一。此次获得药品注册证书的三价流感疫苗，与公司已获批上市的四 价流感病毒裂解疫苗、处于申报上市审评中的四价/三价流感病毒裂解疫苗（儿童型）、处于I/Ⅱ期临床 试验的四价流感病毒裂解疫苗（ZFA02佐剂）及已获批临床的三价流感病毒裂解疫苗（ZFA02佐剂）构 成覆盖全年龄段且种类丰富的流感疫苗系列产品。 ...